Navigation Links
Going viral to target tumors
Date:3/5/2014

March 5, 2014, New York, NY A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors.

Published today in the journal Science Translational Medicine, the study evaluated a combination therapy in which the Newcastle disease virus (NDV), a bird virus not ordinarily harmful to humans, is injected directly into one of two melanoma tumors implanted in mice, followed by an antibody that essentially releases the brakes on the immune response. The researchers report that the combination induced a potent and systemically effective anti-tumor immune response that destroyed the non-infected tumor as well. Even tumor types that have hitherto proved resistant to checkpoint blockade and other immunotherapeutic strategies were susceptible to this combined therapy.

"Many patients have benefited from cancer immunotherapies," says Dmitriy Zamarin, a member of Ludwig's Collaborative Laboratory at Memorial Sloan Kettering Cancer Center (MSK) and lead author of the study together with James Allison of the MD Anderson Cancer Center in Houston, and Jedd Wolchok, Director of the Ludwig Collaborative Laboratory at MSK. "But they have not been effective for all patients, or against all cancer types, since most cancers can potently suppress immune responses. We want to extend the benefits of immunotherapies to more patients and optimize their use against a larger variety of cancers."

Zamarin and his colleagues found that an inflammatory immune response induced in the tumor by NDV primarily accounts for the efficacy of the therapy. The checkpoint blockade antibody used in this study binds CTLA-4, a molecule found on immune cells that acts like a brake (or "checkpoint") on the immune response. A version of this antibody is already used for cancer therapy, and it has proved potent in a clinical trial evaluating its combination with another immunotherapy as well.

The researchers noticed that when NDV was injected into a tumor implanted in mice, cancer-killing immune cells flooded into that tumor. "But we also found, to our surprise, that a similar infiltration of activated immune cells occurred in a distant tumor, one in which the virus was never detected," says Zamarin.

The researchers show that NDV infection alerts T cells of the immune system to the presence of cancer cells, which otherwise suppress immune surveillance and attack. Subsequent injection of the anti-CTLA-4 antibody dials up the incipient anti-tumor response so dramatically that it overcomes the tumor's immune suppression and destroys both NDV-exposed tumors and unexposed tumors. And the effect appears to be durable. When the same tumors are reintroduced into treated animals, they are swiftly eliminated.

Combining the two therapeutic strategies, Zamarin explains, overcomes the limitations of each. Oncolytic virotherapy has long been hindered by the immune system's tendency to disable systemically introduced viruses long before they can target tumors. The current study circumvented this problem by injecting NDV directly into the tumor.

Checkpoint blockade, meanwhile, has failed against tumors that suppress immune detection and attack. The researchers found that NDV prompted the cells of such tumors to betray themselves to the immune system when they informed it about the virus. As a consequence, the strategy even made colorectal and prostate tumors that were resistant to immunotherapy susceptible to checkpoint blockade.

The team also found that NDV could be used to boost the effects of an investigational immunotherapy known as adoptive T cell transfer, in which T cells are taken from patients, trained to recognize specific tumors and then reintroduced into their bodies. Adoptive transfer too has been hampered by the ability of tumors to suppress immune responses.

Pretreatment with NDV may similarly boost other immunotherapies. Additionally, Zamarin notes, NDV could be engineered to package and express immune factors that might further boost desirable elements of the anti-tumor response. The researchers are now working to expand production of NDV and devise protocols to evaluate their combination therapy in early stage clinical trials.


'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Related medicine news :

1. Yoga regulates stress hormones and improves quality of life for women with breast cancer undergoing
2. Study: Resilience in parents of children undergoing stem cell transplant
3. Most women undergoing surgery for vulvar cancer maintain healthy body image and sex life
4. Athletes “Toward Injury Prevention in Sports” TIPS Gets Going in Las Vegas
5. Going Back To Fitness Basics for Big Results: CrossFit Hub Releases New and Funky Exercise Clothing for Workouts
6. Las Vegas Fit Body Boot Camp The Lakes to Host Grand Opening Charity Event with Proceeds Going to Local Non-Profit, The First Tee of Southern Nevada
7. Salon Program Is Going on at Uniwigs.com
8. The Radiosurgery Society® Announces Initial Results from Ongoing, Multi-Center SRS/SBRT Patient Registry
9. Life Support Technologies Group Announces That Hyperbaric Medicine Shown to Benefit Breast Cancer Survivors Undergoing Breast Reconstruction
10. The Forbes Living Talk Show Is Going Green
11. oGoing Launches Android App for Small Business Social Media Marketing, Online Networking and Lead Generation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Philadelphia, PA (PRWEB) , ... June 28, 2017 ... ... will host a one-day corporate governance program for mid-market executives as a kick-off ... will be held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, ...
(Date:6/28/2017)... Vancouver, British Columbia (PRWEB) , ... June 28, ... ... (OTCQB: CNZCF) (FSE: ZEON) is pleased to announce that a two year study ... using the Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... Rolling Meadows, IL (PRWEB) , ... June 27, ... ... they are considering a cosmetic treatment, according to survey data released today by ... Consumer Survey on Cosmetic Dermatologic Procedures indicates the percentage of consumers considering ...
(Date:6/27/2017)... ... 2017 , ... Salucro, the cloud-based payment platform that has ... and provider groups, has announced that it will now offer Parasail’s payment plans ... San Francisco health-finance startup that has launched a series of tech-based products that ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... , June 14, 2017 The Bio Supply ... City of Fremont and the Biomedical ... bio-pharma industry in California by ... executive networking, and fostering workforce development. The primary focus ... growth of start-ups, as well as small and mid-sized ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
Breaking Medicine Technology: